Parkinson's Disease Exercise TMS PET Study

Parkinson Disease Clinical Trial

Official title:

Exercise and Parkinson's Disease: The Basis for Motor and Cognitive Benefits

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02265900
• Other study ID #: H14-02200
• Status: Terminated
• Phase: N/A
• Start date: November 2014
• Est. completion date: March 12, 2020

Study information

• Verified date: March 2021
• Source: Pacific Parkinson's Research Centre
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The therapeutic effects of exercise in Parkinson's disease (PD) are commonly reported, however the mechanisms are unknown. The purpose of this study is to investigate the potential mechanisms of exercise in the brain for the treatment of PD.

Description:

Positron Emission Tomography will be used to measure dopamine neuron density, endogenous dopamine release and neuroimflammation. We will also use functional magnetic resonance imaging (fMRI) to measure brain activity. Assessments will be conducted before and after a 12-week exercise intervention and 3-year follow-up. Participants will be randomly allocated into either an aerobic or a stretching intervention. Clinical measures of motor function, cognition and mood will also be assessed.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 26
• Est. completion date: March 12, 2020
• Est. primary completion date: March 12, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria: Diagnosed with Parkinson's Disease, Exercise less than 3x per week.

Exclusion Criteria. Describe which potential participants will be excluded from participation, and list the criteria for their exclusion.

1. atypical Parkinson syndrome (progressive supranuclear palsy, multiple system atrophy, drug-induced etc.);

2. significant osteoporosis or arthritis;

3. other neurological disease/complications (e.g. myopathy, stroke, brain lesion, MS);

4. self-reports claustrophobia;

5. history of cancer within 5 years of study participation;

6. high dose of radiation from other procedures within the year;

7. not able to tolerate being off PD medication for up to 24 hours;

8. a female subject who is breast-feeding or pregnant.

9. Subjects who regularly use anti-inflammatories (only excluded for PBR scans).

Exclusion criteria for MRI scanning and magnetic stimulation from repetitive Transcranial Magnetic Stimulation (rTMS) scanning includes:

1. artificial heart valve;

2. brain aneurysm clip;

3. electrical stimulator for nerves or bones;

4. ear or eye implant;

5. implanted drug infusion pump;

6. coil, catheter, or filter in any blood vessel;

7. orthopedic hardware (artificial joint, plate, screws);

8. other metallic prostheses;

9. shrapnel, bullets, or other metal fragments;

10. surgery or tattoos (including tattooed eyeliner) in the last six weeks;

11. brain surgery

12. have a cardiac pacemaker, wires or defibrillator;

13. have had an injury where a piece of metal lodged in the eye or orbit;

14. have a ferromagnetic aneurysm clip; and

15. have a history of seizures/epilepsy

16. history of severe or uncontrolled headaches/migraines

17. taking medications that lower seizure threshold (e.g. amitryptiline, haloperidol)

Subjects may be excluded following study enrollment if they meet any of the following exclusion criteria:

1. significant cognitive impairment or depression;

2. significant or unstable cardiovascular or respiratory disease - all subjects will undergo a screening exercise bicycle stress test; or

3. failure to comply with the exercise or stretching intervention program by not completing at least 30 of the 36 exercise classes.

4. Severe/multiple head trauma(s)

Related Conditions & MeSH terms

• Parkinson Disease

Intervention

Other:
• Exercise
One type of exercise
• Exercise
A different type of exercise

Locations

Country	Name	City	State
Canada	Pacific Parkinson's Research Centre	Vancouver	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Pacific Parkinson's Research Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Dopamine release measured by RAC PET		4 months